During this session, panelists discussed the current market outlook for CROs and the key differentiators making them attractive to private equity investors, such as therapeutic area (TA) specialization, their ability to ensure diversity in clinical trials and the integration of artificial intelligence (AI) into their value offerings. They also discussed how the expectations of CRO customers – primarily large pharmaceutical companies – are rising, with a renewed focus on speed and quality in trial execution. Here are key takeaways.
Read the full article: Key Takeaways | Contract Research Organizations (CROs) //
Source: https://www.mwe.com/insights/key-takeaways-contract-research-organizations-cros/